Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senza5 CART5 in relapsed/refractory CD5+ T-cell NHL
NCT06420089Phase 1Recruiting
- Sponsor
- Vittoria Biotherapeutics
- Start
- Oct 2024
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of VIPER-101 in T-cell non-Hodgkin lymphoma (2 arms), sponsored by Vittoria Biotherapeutics. Primary endpoint: Recommended Phase 2 Dose at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
VIPER-101
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06420089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420089.